We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Tissue-Based Heart Valves Better for the Middle-Aged

By HospiMedica International staff writers
Posted on 26 Jan 2016
Patients between 40 and 70 years of age who undergo aortic valve replacement (AVR) may fare better with tissue-based valves rather than metal-based ones, according to a new study.

Researchers at the University of Sydney (Australia; sydney.edu.au) and Royal Prince Alfred Hospital (Sydney, NSW, Australia) conducted a database search and identified 13 studies comparing mechanical and bioprosthetic valves in AVR patients aged 40 to 70 years. More...
The results revealed that 15-years post-surgery, no difference was found in survival, stroke rate, or rate of endocarditis among patients with either valve; however, each patient group developed a different set of complications.

Patients with bioprosthetic valves were twice as likely as mechanical valve patients to need re-operation due to worn-out valves, while patients with mechanical valves were twice as likely to experience a major bleeding event or a blood clot. Because patients with major bleeding had a significant increase of death compared to those needing reoperation, the researchers concluded that bioprosthetic valves should strongly be considered for patients in this age group, though valve choice should be individualized for each patient. The study was published on January 12, 2016, in the Annals of Thoracic Surgery.

“We combined the best available evidence comparing mechanical valves versus bioprosthetic valves to determine the risks and benefits to patients following surgery, depending on the type of valve they received,” said lead author James Wu, BMusStudies, of the University of Sydney. “We hope that our results can give future patients needing AVR more information to help them choose the appropriate replacement valve for their condition.”

“This is a complex decision that requires up-to-date evidence. There are options to reduce the bleeding risk of mechanical valves, so, ideally, a discussion with both the surgeon and cardiologist is warranted to take into account an individual's circumstances,” concluded senior author Paul Bannon, MBBS, PhD.

Mechanical valves are the most long-lasting type of replacement valve, but patients will usually require blood thinners to stop clots from forming, as they can lodge in valve flaps or hinges which can cause a malfunction or form emboli. Bioprosthetic tissue can last 10–20 years, but usually do not require long-term use of medication. On the other hand, a young person with a bioprosthetic valve replacement, the need for additional surgery or another valve replacement later in life is highly likely.

Related Links:

University of Sydney
Royal Prince Alfred Hospital



Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hybrid Arch Device
Neo EDE
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: 123RF

AI Platform Screens for Amyloid Cardiomyopathy Using ECG Images

Amyloid cardiomyopathy is a heart disease caused by deposits of misfolded proteins in the cardiac muscle. It is often missed until patients develop serious complications such as heart failure.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.